Galanin Reduces Myocardial Ischemia/Reperfusion Injury in Rats with Streptozotocin Diabetes

Area of Science:

• Cardiovascular Research
• Diabetology
• Mitochondrial Physiology

Background:

• Diabetes mellitus (DM) significantly worsens outcomes of myocardial ischemia-reperfusion injury (IRI).
• Effective treatments for IRI in diabetic patients are urgently needed.
• Diabetic myocardium exhibits impaired mitochondrial function and energy metabolism.

Purpose of the Study:

• To investigate the therapeutic potential of galanin (G) in a rat model of type 1 diabetes mellitus (DM1) with myocardial IRI.
• To assess the effects of G on infarct size, mitochondrial function, and energy status in the diabetic heart.

Main Methods:

• Type 1 diabetes mellitus (DM1) induced by streptozotocin in rats.
• Myocardial IRI modeled by coronary artery occlusion and reperfusion.
• Galanin (G) administered intravenously prior to reperfusion; infarct size, plasma CK-MB, mitochondrial respiration, and adenine nucleotide metabolism assessed.

Main Results:

• Galanin (G) significantly reduced myocardial infarct (MI) size by 40% and plasma creatine kinase MB (CK-MB) activity by 28% in diabetic rats.
• G improved mitochondrial respiration, including state 3 respiration and respiratory control, in the ischemic-reperfused area.
• G administration preserved ATP levels, total adenine nucleotide pool, adenylate energy charge, and reduced creatine loss in the diabetic myocardium.

Conclusions:

• Galanin (G) demonstrates protective effects against myocardial ischemia-reperfusion injury in the context of type 1 diabetes mellitus.
• G's benefits are linked to improved mitochondrial function and energy metabolism in the diabetic heart.
• Galanin shows promise as a therapeutic agent for managing myocardial IRI complicated by diabetes.